信迪利单抗联合白蛋白紫杉醇治疗肺鳞状细胞癌的效果及对免疫功能、肿瘤标志物的影响

Effects of Sintilimab combined with albumin paclitaxel on lung squamous cell carcinoma and its influences on immune function and tumor markers

目的观察信迪利单抗联合白蛋白紫杉醇治疗肺鳞状细胞癌(LSCC)的效果及对免疫功能、肿瘤标志物的影响。方法回顾性分析2019年2月至2022年2月乐平市人民医院收治的80例LSCC患者的临床资料,按照治疗方法,将其分为对照组(40例)与观察组(40例),对照组采用白蛋白紫杉醇治疗,观察组采用信迪利单抗联合白蛋白紫杉醇治疗。比较两组患者临床疗效,治疗前后免疫功能、肿瘤标志物水平及不良反应发生情况。结果观察组患者治疗后的客观缓解率(ORR)、疾病控制率(DCR)高于对照组,差异有统计学意义(P<0.05);观察组患者治疗后的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)及NK细胞均高于对照组,差异有统计学意义(P<0.05);观察组患者治疗后的CD4^(+)、CD4^(+)/CD8^(+)水平高于本组治疗前,差异有统计学意义(P<0.05);对照组患者治疗后的CD3^(+)、CD4^(+)及NK细胞水平低于本组治疗前,差异有统计学意义(P<0.05);两组患者治疗后的肿瘤标志物水平低于本组治疗前,差异有统计学意义(P<0.05);观察组患者治疗后的肿瘤标志物水平低于对照组,差异有统计学意义(P<0.05);两组患者治疗期间不良反应发生情况比较,差异无统计学意义(P>0.05)。结论与白蛋白紫杉醇治疗比较,信迪利单抗联合白蛋白紫杉醇对LSCC疗效更佳,在改善免疫功能、降低肿瘤标志物水平方面优势更显著。

Objective To observe the effect of Sindilizumab combined with albumin paclitaxel in the treatment of lung squamous cell carcinoma(LSCC)and its effects on immune function and tumor markers.Methods The clinical data of 80 patients with LSCC admitted to Leping People's Hospital from February 2019 to February 2022 were retrospectively analyzed.According to treatment methods,they were divided into control group(40 cases)and observation group(40 cases).The control group was treated with albumin-paclitaxel,and the observation group was treated with Sindellizumab combined with albumin-paclitaxel.The clinical efficacy,immune function,tumor marker level and the occurrence of adverse reactions were compared between the two groups.Results After treatment,the objective response rate(ORR)and disease control rate(DCR)in observation group were higher than those in control group,with statistical significances(P<0.05).After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)and NK cells in observation group were higher than those in control group,and the differences were statistically significant(P<0.05).The levels of CD4^(+)and CD4^(+)/CD8^(+)in observation group were higher after treatment than those before treatment,and the differences were statistically significant(P<0.05).The levels of CD3^(+),CD4^(+)and NK cells in control group after treatment were lower than those before treatment,and the differences were statistically significant(P<0.05).The levels of tumor markers in two groups after treatment were lower than those before treatment,and the differences was statistically significant(P<0.05).The levels of tumor markers in observation group were lower than those in control group after treatment,and the differences were statistically significant(P<0.05).There was no significant difference in the occurrence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Compared with albumin-paclitaxel,Sindilizumab combined with albumin-paclitaxel has better efficacy in the treatment of LSCC,and has more significant advantages in improving immune function and reducing the level of tumor markers.